(MENAFN- PR Newswire) OR YEHUDA,
Israel, Oct. 31, 2022 /PRNewswire/ -- BeWeld Medical, developer of a disruptive technology designed to automate the manufacturing processes of implanted medical devices, has signed a strategic investment agreement with global medical technology leader Boston Scientific.
'BeWeld's technology has potential to advance the automation of manufacturing processes for medical devices that are used on patients around the world,' said Shai Policker, CEO of MEDX Xelerator and chairman of BeWeld. 'At just over a year old, BeWeld is one of our youngest portfolio companies and this agreement represents an important milestone that will enable us to further test and refine the company's innovative technology.'
About BeWeld
BeWeld was founded in 2021 by the MEDX Xelerator based on intellectual property developed by Professor Daniel Cohn and Abeer Khalaialh at the Hebrew University in Jerusalem. The company is led by CEO Asaf Gordon and CTO Ms. Khalaialh.
Press contact: Marjie HadadGeneral ManagerMust Have Communication & Consulting+972-54-536-5220+917-790-1178
SOURCE BeWeld Medical
MENAFN31102022003732001241ID1105105373
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment